Lilit Karapetyan

12PUBLICATIONS
26CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Molecular targetsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Radiation therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Aug 01, 2026
Dual stimulation of CD40 and 41BB pathways during ex-vivo TIL expansion enhances CD8+ T cell expansion.

|Nov 24, 2025
Lead-in therapy targeting PD1 and/or LAG3 imposes distinct immune phenotypes in first-line treatment of metastatic melanoma.

Lilit Karapetyan, Anthony R Cillo, Shuaichao Wang

|Nov 13, 2024
Differences in the pathological, transcriptomic, and prognostic implications of lymphoid structures between primary and metastatic cutaneous melanomas.

Lilit Karapetyan, Aofei Li, Danielle Vargas De Stefano

|Sep 06, 2024
Durability of response to immune checkpoint blockade following treatment discontinuation and efficacy of rechallenge in advanced Merkel cell carcinoma.

Tanya Ramadoss, Matthew Nichols, Christian Palacios

|Dec 06, 2023
Differential requirements for CD4+ T cells in the efficacy of the anti-PD-1+LAG-3 and anti-PD-1+CTLA-4 combinations in melanoma flank and brain metastasis models.

Manali S Phadke, Jiannong Li, Zhihua Chen

|Jun 22, 2023
Radiation dose, schedule, and novel systemic targets for radio-immunotherapy combinations.

Lilit Karapetyan, Uzoma K Iheagwara, Adam C Olson

Pageof 2

Frequent Collaborators

2 joint publications

Jason J Luke

1 joint publications

Heather Laird-Fick

1 joint publications

Mohamed Hassanein

1 joint publications

Xi Yang